Werewolf Therapeutics Management
Management criteria checks 3/4
Werewolf Therapeutics' CEO is Dan Hicklin, appointed in Oct 2017, has a tenure of 6.67 years. total yearly compensation is $1.37M, comprised of 42.7% salary and 57.3% bonuses, including company stock and options. directly owns 1.49% of the company’s shares, worth $1.51M. The average tenure of the management team and the board of directors is 3.5 years and 4.7 years respectively.
Key information
Dan Hicklin
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 42.7% |
| CEO tenure | 6.7yrs |
| CEO ownership | 1.5% |
| Management average tenure | 3.5yrs |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$42m |
| Dec 31 2023 | US$1m | US$583k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$37m |
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$50m |
| Dec 31 2022 | US$2m | US$530k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$60m |
| Jun 30 2022 | n/a | n/a | -US$62m |
| Mar 31 2022 | n/a | n/a | -US$115m |
| Dec 31 2021 | US$2m | US$498k | -US$202m |
| Sep 30 2021 | n/a | n/a | -US$205m |
| Jun 30 2021 | n/a | n/a | -US$197m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$3m | US$425k | -US$28m |
Compensation vs Market: Dan's total compensation ($USD1.37M) is above average for companies of similar size in the US market ($USD689.64K).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Hicklin (60 yo)
6.7yrs
Tenure
US$1,366,904
Compensation
Dr. Daniel J. Hicklin, Ph D., also known as Dan, Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019. He serves on its Board of Dire...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.7yrs | US$1.37m | 1.49% $ 1.5m | |
| CFO, Treasurer & Assistant Secretary | 3.3yrs | US$815.59k | 0% $ 0 | |
| Chief Medical Officer | 3.6yrs | US$855.77k | 0% $ 0 | |
| Senior Vice President of Research | no data | no data | no data | |
| Chief Technology Officer | 3yrs | US$3.86m | no data | |
| Chief Business Officer | 3.8yrs | no data | no data |
3.5yrs
Average Tenure
64yo
Average Age
Experienced Management: HOWL's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.7yrs | US$1.37m | 1.49% $ 1.5m | |
| Independent Chairman of the Board | 6.7yrs | US$104.03k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$78.66k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.6yrs | US$62.32k | 0.036% $ 36.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board & Director | 5.8yrs | no data | 0.033% $ 33.7k | |
| Independent Director | 4.8yrs | US$78.53k | 4.71% $ 4.8m | |
| Independent Director | 2.7yrs | US$65.36k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$72.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.7yrs
Average Tenure
61yo
Average Age
Experienced Board: HOWL's board of directors are considered experienced (4.7 years average tenure).